This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BioSante Alters Terms Of Cell Genesys Deal

NEW YORK (AP) ¿ BioSante Pharmaceuticals Inc. said it is adjusting its exchange ratio with Cell Genesys Inc. as the companies prepare to complete their all-stock tie up.

BioSante agreed to acquire Cell Genesys in June in a deal then valued at $38 million. Late Tuesday, the company said Cell Genesys shareholders will get 0.1828 shares of BioSante for every Cell Genesys share held. It raised that rate from 0.1615 shares because Cell Genesys has $23.8 million on hand, or $1.7 million more than expected.

The two companies will hold meetings on Sept. 30 where shareholders will vote on the deal. Pending approval, they said the deal will close shortly after that. If the deal is completed, the company will retain the BioSante name, and current BioSante shareholders will own 62 percent of the combined company.

BioSante of Lincolnshire, Ill., said the combined company would focus primarily on LibiGel, a topical testosterone gel intended to treat sexual dysfunction in women. The company will also look to develop Cell Genesys' cancer treatment GVAX. That may include testing GVAX in combination with BioVant, a BioSante product designed to make vaccines more effective. It could also license Cell Genesys technologies to other companies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs